BAT CEO: to ramp up ‘next-generation’ tobacco capacity in Italy, plans €500 mln investment in Trieste plant by 2027

Feb.03
BAT CEO: to ramp up ‘next-generation’ tobacco capacity in Italy, plans €500 mln investment in Trieste plant by 2027
British American Tobacco (BAT) CEO Tadeu Marroco said the group will continue to invest in equipment and technology in Italy and expand capacity for next-generation tobacco products such as e-cigarettes and heated tobacco. BAT’s Trieste innovation hub is slated to receive a total investment of 500 million euros by 2027 and add 16 new production lines.

Key points at a glance

 

  • Stepping up manufacturing in Italy: Continued spending on equipment and technology, with expanded capacity for smoke-free products.
  • Localised supply chain: Marroco said roughly 80% of machinery purchased for BAT factories worldwide comes from Italian companies, while more than 80% of BAT’s suppliers in Italy are domestic SMEs.
  • Limited impact from higher excise duties: BAT expects a manageable effect from Italy’s multi-year excise increases and said it pays about 2 billion euros a year in Italy in excise and VAT.
  • Securing leaf tobacco purchases: BAT plans to buy up to 15,000 tonnes of Italian tobacco in 2026–2028, supporting more than 400 SMEs and around 6,000 jobs.
  • Capacity expansion and sales mix: Trieste is adding 16 production lines; next-generation products account for about 18% of group revenue and around 45% in Italy, Marroco said.

 


 

2Firsts, Feb 3, 2026

 

According to Milano Finanza, Marroco said BAT will keep investing in production equipment and technology in Italy while building capacity for next-generation tobacco products, including vaping and heated tobacco, and maintaining its local tobacco leaf procurement. He spoke during a visit to Rome for meetings with institutions and stakeholders.

 

Marroco said around 80% of machinery BAT buys for its factories worldwide is supplied by Italian companies, and that more than 80% of BAT’s suppliers in Italy are domestic small and medium-sized enterprises. He cited Brazil as a contrasting case, saying a ban on e-cigarettes there has fuelled the spread of illicit devices, undermined oversight and public finances, and increased health risks.

 

On taxation, Italy’s latest budget includes further multi-year increases in excise duties on cigarettes and tobacco products, rising to as much as 0.15 euros per pack in 2026, with an expected 213 million euros in additional revenue this year. Marroco said the measures had been planned and would have a limited impact on BAT’s business. He added that BAT pays about 2 billion euros a year to the Italian state in excise and VAT. He also said fiscal stability helps deter tax evasion and curb illicit trade, noting the illicit market in Italy accounts for about 4.5%.

 

Looking at BAT’s long-term commitments in Italy, Marroco recalled the group’s 2004 acquisition of Italy’s state tobacco assets for 2.3 billion euros and said Italy remains one of BAT’s key markets. He said BAT will purchase up to 15,000 tonnes of Italian tobacco over 2026–2028, supporting more than 400 SMEs employing around 6,000 people, under a three-year protocol renewed in 2025 between BAT Italy and the Ministry of Agriculture, Food Sovereignty and Forests (MASAF).

 

On manufacturing, Marroco said BAT opened its Trieste innovation hub in 2023 and plans to invest a total of 500 million euros by 2027. As 16 additional production lines announced last September ramp up to full capacity, the site is expected to generate employment impacts for about 2,700 people over five years, while total capacity is set to double compared with the original industrial plan, which envisaged up to 12 lines by 2027.

 

On the group’s transition targets, Marroco said BAT aims for non-combustible products to account for 50% of revenue by 2035. He said the share currently stands at about 18% at group level, with Italy at around 45%. Marroco added that BAT invests about 350 million pounds a year in scientific research. On results for 2025, he said BAT would present them shortly and that he was optimistic about growth, citing improved performance in the U.S. market, which he said represents about 50% of group revenue, while noting lengthy U.S. FDA authorisation processes can slow innovation and increase the share of illicit products.

 

Cover image source: Tobacco Reporter

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

BAT CFO Dragos Constantinescu Takes Office, Returning After Seven Years and Former Asahi Europe Leadership Role
BAT CFO Dragos Constantinescu Takes Office, Returning After Seven Years and Former Asahi Europe Leadership Role
Dragos Constantinescu has officially taken up his role as Chief Financial Officer and Executive Director at British American Tobacco (BAT). He previously spent 16 years at BAT across finance and general management roles in Europe before joining Asahi in 2019 and becoming CEO of Asahi Europe & International in 2025. His return comes as BAT continues to advance its “A Better Tomorrow” transformation.
BAT
Sep.01
2Firsts On-Site | CTIHK Showcases Nicotine Pouches, Heated Tobacco and Chinese Cigars at InterTabac 2026
2Firsts On-Site | CTIHK Showcases Nicotine Pouches, Heated Tobacco and Chinese Cigars at InterTabac 2026
At InterTabac 2026 in Dortmund, China Tobacco International (HK) Company Limited (CTIHK) is exhibiting across two separate booths in Hall 5 and Hall 4. Products observed by 2Firsts include heated tobacco products, nicotine pouches, Chinese cigars and tobacco leaf. Nicotine pouch products on display include TOOP, Shuangxi and Ashima.
Market
Sep.16
Product | BAT Expands VELO Peach Ice Medium to FamilyMart Stores Nationwide in Japan
Product | BAT Expands VELO Peach Ice Medium to FamilyMart Stores Nationwide in Japan
British American Tobacco Japan (BAT Japan) expanded VELO Peach Ice Medium to FamilyMart stores nationwide in Japan from September 7, 2026. The oral tobacco product first launched on July 6 and had previously been sold through VELO's official online store, glo Store Ginza and tobacco retailers. It combines peach flavor with menthol cooling at a Medium strength level and is priced at JPY 360. Japanese tobacco retailers list 15 pouches per pack. The move adds the new SKU to an existing nationwide FamilyMart distribution network for VELO rather than marking the brand's first entry into the convenience-store chain.
Sep.15
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
At the 2026 New Approaches Summit in New York, former FDA Center for Tobacco Products Director Mitch Zeller called for the tobacco harm reduction debate to shift from the traditional “end game” toward defining a desired “end state.” He also highlighted unresolved concerns around dual use, argued that biomarkers of exposure may be more meaningful than cigarettes-per-day in assessing risk reduction, and said nicotine misperceptions remain a major barrier to public health progress.
Sep.25
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-listed consumer goods group Supreme plc says it continues to expect FY27 trading to meet market expectations as the Vaping Products Duty takes effect on October 1, while maintaining a comparatively positive view of the new tax and compliance regime. Supreme has said the framework could increase compliance complexity for smaller operators and contribute to market consolidation, while its manufacturing, compliance and distribution scale may allow it to gain share. Its 88Vape brand will retain its value positioning.
Sep.18
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26